CL2009002173A1 - Composicion farmaceutica con una liberacion pulsatil de sildenafil que posee fraccion una liberacion inmediata que contiene 5 a 100 mg de sildenafil y una fraccion de liberacion controlada que contiene 25 a 150 mg de sildenafil; proceso para prepararla, util para tratar disfuncion erectil. - Google Patents
Composicion farmaceutica con una liberacion pulsatil de sildenafil que posee fraccion una liberacion inmediata que contiene 5 a 100 mg de sildenafil y una fraccion de liberacion controlada que contiene 25 a 150 mg de sildenafil; proceso para prepararla, util para tratar disfuncion erectil.Info
- Publication number
- CL2009002173A1 CL2009002173A1 CL2009002173A CL2009002173A CL2009002173A1 CL 2009002173 A1 CL2009002173 A1 CL 2009002173A1 CL 2009002173 A CL2009002173 A CL 2009002173A CL 2009002173 A CL2009002173 A CL 2009002173A CL 2009002173 A1 CL2009002173 A1 CL 2009002173A1
- Authority
- CL
- Chile
- Prior art keywords
- sildenafil
- fraction containing
- prepare
- pharmaceutical composition
- release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Composición farmacéutica de liberación pulsátil de sildenafil que comprende una fracción de liberación inmediata y una de liberación controlada con partículas recubiertas que contienen un agente súper desintegrante, un polímero de solubilidad ph-dependiente, al menos un polímero de solubilidad ph independiente; y proceso para prepararla.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2008/003466 WO2010067140A1 (es) | 2008-12-12 | 2008-12-12 | Composicion de liberacion pulsatil de sildenafil y proceso para prepararla |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009002173A1 true CL2009002173A1 (es) | 2010-04-09 |
Family
ID=42242382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009002173A CL2009002173A1 (es) | 2008-12-12 | 2009-12-11 | Composicion farmaceutica con una liberacion pulsatil de sildenafil que posee fraccion una liberacion inmediata que contiene 5 a 100 mg de sildenafil y una fraccion de liberacion controlada que contiene 25 a 150 mg de sildenafil; proceso para prepararla, util para tratar disfuncion erectil. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20110244050A1 (es) |
EP (1) | EP2374460A4 (es) |
AR (1) | AR071970A1 (es) |
BR (1) | BRPI0823356A2 (es) |
CL (1) | CL2009002173A1 (es) |
CR (1) | CR20110322A (es) |
EC (1) | ECSP11011194A (es) |
MX (1) | MX339136B (es) |
NI (1) | NI201100119A (es) |
PA (1) | PA8853801A1 (es) |
PE (1) | PE20100471A1 (es) |
UY (1) | UY32304A (es) |
WO (1) | WO2010067140A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014018149B1 (pt) * | 2012-01-27 | 2020-09-29 | Siegfried Rhein S.A. De C.V | Composição farmacêutica de nitazoxanida |
EA019381B1 (ru) * | 2012-07-20 | 2014-03-31 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Таблетка, содержащая ингибитор фосфодиэстеразы пятого типа, способ ее получения и ее применение |
KR101340733B1 (ko) * | 2012-12-31 | 2013-12-12 | (주) 에프엔지리서치 | 신규한 마이크로그래뉼 제형 |
CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
WO2017168174A1 (en) * | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
WO2023037394A1 (en) * | 2021-09-13 | 2023-03-16 | Amman Pharmaceutical Industries Company | A pharmaceutical composition of sildenafil and a formulation thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9301192D0 (en) * | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB9612514D0 (en) | 1996-06-14 | 1996-08-14 | Pfizer Ltd | Novel process |
KR20000069899A (ko) | 1997-01-06 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 속방성 및 미각 차폐성 약제학적 용량 형태 |
CA2235642C (en) | 1998-05-15 | 2007-11-13 | Torcan Chemical Ltd. | Processes for preparing sildenafil |
UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
CN1499960A (zh) * | 2001-03-13 | 2004-05-26 | ����˹��ҩ�﹫˾ | 时间治疗剂型 |
US8512751B2 (en) * | 2004-12-20 | 2013-08-20 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
BRPI0716196A2 (pt) * | 2006-08-31 | 2013-11-12 | Eurand Inc | Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos. |
-
2008
- 2008-12-12 EP EP08878690.0A patent/EP2374460A4/en not_active Withdrawn
- 2008-12-12 US US13/139,261 patent/US20110244050A1/en not_active Abandoned
- 2008-12-12 BR BRPI0823356-0A patent/BRPI0823356A2/pt not_active Application Discontinuation
- 2008-12-12 WO PCT/IB2008/003466 patent/WO2010067140A1/es active Application Filing
- 2008-12-12 MX MX2011005752A patent/MX339136B/es active IP Right Grant
-
2009
- 2009-05-29 AR ARP090101956A patent/AR071970A1/es unknown
- 2009-12-07 UY UY0001032304A patent/UY32304A/es not_active Application Discontinuation
- 2009-12-07 PE PE2009001294A patent/PE20100471A1/es not_active Application Discontinuation
- 2009-12-11 PA PA20098853801A patent/PA8853801A1/es unknown
- 2009-12-11 CL CL2009002173A patent/CL2009002173A1/es unknown
-
2011
- 2011-06-10 NI NI201100119A patent/NI201100119A/es unknown
- 2011-06-10 CR CR20110322A patent/CR20110322A/es unknown
- 2011-07-11 EC EC2011011194A patent/ECSP11011194A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX339136B (es) | 2016-05-13 |
UY32304A (es) | 2010-05-31 |
NI201100119A (es) | 2012-08-03 |
CR20110322A (es) | 2011-10-25 |
BRPI0823356A2 (pt) | 2015-06-16 |
EP2374460A1 (en) | 2011-10-12 |
PA8853801A1 (es) | 2010-07-27 |
US20110244050A1 (en) | 2011-10-06 |
AR071970A1 (es) | 2010-07-28 |
PE20100471A1 (es) | 2010-07-22 |
EP2374460A4 (en) | 2013-08-21 |
ECSP11011194A (es) | 2011-09-30 |
MX2011005752A (es) | 2011-08-12 |
WO2010067140A1 (es) | 2010-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009002173A1 (es) | Composicion farmaceutica con una liberacion pulsatil de sildenafil que posee fraccion una liberacion inmediata que contiene 5 a 100 mg de sildenafil y una fraccion de liberacion controlada que contiene 25 a 150 mg de sildenafil; proceso para prepararla, util para tratar disfuncion erectil. | |
AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
ES2526606T3 (es) | Composición farmacéutica sólida que comprende amlodipina y losartán | |
AR083395A1 (es) | Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico | |
CL2008003653A1 (es) | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. | |
CR11723A (es) | Agente para tratar enfermedad | |
CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
UY31816A (es) | Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras | |
TW200744665A (en) | Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof | |
TN2009000292A1 (en) | Formulations for cancer treatment | |
CL2009001766A1 (es) | Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica. | |
CU24349B1 (es) | Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer | |
CR9704A (es) | Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma. | |
MX2009006823A (es) | Formas de dosificacion solidas de desintegracion oral que comprenden progestina y metodos para hacer y usar las mismas. | |
MX2020004099A (es) | Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo. | |
CL2008001782A1 (es) | Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion. | |
ECSP099071A (es) | Agonistas de ep2 | |
BRPI0908124A2 (pt) | Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença | |
WO2008010991A3 (en) | Methods and compositions for the treatment of cancer | |
MX2009005114A (es) | Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus. | |
CL2009001215A1 (es) | Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer. | |
CL2011002233A1 (es) | Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico. | |
BRPI0606373A2 (pt) | composição de xarope compreendendo dexibuprofeno como ingrediente ativo e método para a preparação da mesma | |
CO6280474A2 (es) | Composicion farmaceutica para el tratamiento de la eyaculacion precoz | |
BRPI0506630A (pt) | composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada |